CA
NZ
UK
AU
IND
US
The transition from earlier-stage clinical testing into a Phase 2b trial represents a meaningful milestone in a drug candidate's development pathway. Phase 2b studies are typically larger and more rigorously controlled than initial Phase 2a proof-of-concept trials, designed to further establish both efficacy and …
The data presented at AAIC illustrated the diverse ways individuals respond to and cope with cognitive and functional changes associated with early Alzheimer's disease. This kind of characterization, focused on patient heterogeneity in disease experience rather than a specific, quantifiable efficacy or safety endpoint, …
Rani's fundamental technology proposition is built around converting biologic drugs, which have traditionally required injection due to their vulnerability to degradation in the gastrointestinal tract, into oral formulations capable of achieving comparable systemic drug exposure. Achieving systemic exposure that exceeds 150% of a matched …
The distinction between internally generated preclinical data and independently reproduced data is one of the most important quality signals in early-stage drug development. Regulatory agencies like the FDA place significant weight on the reproducibility of preclinical findings when evaluating IND applications, since a therapeutic …
Among the pipeline updates investors are tracking is reboxetine, also known as AXS-12, evaluated in the ENCORE trial for narcolepsy, a chronic neurological sleep disorder characterized by excessive daytime sleepiness and, in some cases, sudden muscle weakness triggered by strong emotions. The program carries …
Under the terms of the agreement, Senti will receive contingent value rights, or CVRs, that could total $60 million. CVRs are a common mechanism in biotech divestitures and M&A transactions, structured to give the selling company continued financial upside tied to the future success …
An increase in authorized shares does not itself issue new shares or dilute existing shareholders; rather, it raises the ceiling on how many shares the company is legally permitted to issue in the future without seeking additional shareholder approval. Companies often seek this kind …
Independent confirmation of preclinical findings, typically conducted by a contract research organization or other third-party laboratory unaffiliated with the company's own internal research team, adds meaningful credibility to a drug candidate's underlying scientific rationale. It reduces the risk that observed anti-tumor effects were specific …
The offering involves the sale of 8,571,429 common shares along with equivalent warrants, priced at a unit price of $1.05. Given the stock's closing price of $0.89, the offering was priced at a level above where the stock ultimately settled, though the exact relationship …
The core value proposition of this new tool is its ability to facilitate expedited screening and prioritization of fungicide leads based solely on chemical architecture. Traditional agrochemical discovery typically requires extensive laboratory testing to assess how candidate compounds interact with target fungal pathogens, a …
Please wait processing your request...